MACK logo

Merrimack Pharmaceuticals, Inc.

MACK

MACK: Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.

more

Show MACK Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of MACK by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by MACK's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Inhibiting ataxia telangiectasia and rad3-related protein (atr) Feb. 25, 2020
  • Patent Title: Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies Apr. 30, 2019
  • Patent Title: Biomarkers for predicting outcomes of cancer therapy with erbb3 inhibitors Jan. 22, 2019
  • Patent Title: Compositions and methods for delivering nucleic acid to a cell Oct. 02, 2018
  • Patent Title: Antibodies against epidermal growth factor receptor (egfr) and uses thereof Sep. 11, 2018
  • Patent Title: Bi-specific fusion proteins May. 29, 2018
  • Patent Title: Compositions and methods for non-invasive imaging May. 15, 2018
  • Patent Title: Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies Apr. 10, 2018
  • Patent Title: Dosage and administration of anti-egfr therapeutics Mar. 20, 2018
  • Patent Title: Combination therapy for treating her2-positive cancers Mar. 13, 2018
  • Patent Title: Antibodies against epidermal growth factor receptor (egfr) and uses thereof Feb. 27, 2018
  • Patent Title: Antibodies against epidermal growth factor receptor (egfr) and uses thereof Feb. 06, 2018
  • Patent Title: Method of treating myocardial infarction by administering a bi-specific fusion protein Aug. 01, 2017
  • Patent Title: Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies Jun. 27, 2017
  • Patent Title: Dosage and administration of anti-egfr therapeutics May. 23, 2017
  • Patent Title: Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents Apr. 04, 2017
  • Patent Title: Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies Jan. 31, 2017
  • Patent Title: Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies Dec. 27, 2016
  • Patent Title: Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers Dec. 13, 2016
  • Patent Title: Compositions and methods for non-invasive imaging Dec. 06, 2016
  • Patent Title: Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan Nov. 15, 2016
  • Patent Title: Antibodies against the ectodomain of erbb3 and uses thereof Nov. 08, 2016
  • Patent Title: Anti-c-met tandem fc bispecific antibodies Oct. 04, 2016
  • Patent Title: Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan Sep. 27, 2016
  • Patent Title: Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan Jun. 14, 2016
  • Patent Title: Combination therapies comprising anti-erbb3 agents May. 24, 2016
  • Patent Title: Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan May. 17, 2016
  • Patent Title: Bi-specific fusion proteins Jan. 19, 2016
  • Patent Title: Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents Jan. 05, 2016
  • Patent Title: Antibodies against epidermal growth factor receptor (egfr) and uses thereof Jan. 05, 2016
  • Patent Title: Antibodies against epidermal growth factor receptor (egfr) and uses thereof Jun. 02, 2015
  • Patent Title: Liposomes useful for drug delivery Mar. 31, 2015
  • Patent Title: Antibodies against erbb3 and uses thereof Feb. 24, 2015
  • Patent Title: Human serum albumin linkers and conjugates thereof Jan. 06, 2015
  • Patent Title: Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers Nov. 25, 2014
  • Patent Title: Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug Nov. 04, 2014
  • Patent Title: Liposomes useful for drug delivery Apr. 22, 2014
  • Patent Title: Bi-specific fusion proteins for tissue repair Apr. 08, 2014
  • Patent Title: Methods of treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligands with monoclonal and oligoclonal anti-egfr antibodies Apr. 08, 2014
  • Patent Title: Antibodies against the ectodomain of erbb3 and uses thereof Apr. 08, 2014
  • Patent Title: Liposomes useful for drug delivery to the brain Feb. 25, 2014
  • Patent Title: Methods and systems for predicting response of cells to a therapeutic agent Jan. 07, 2014
  • Patent Title: Bispecific anti-igf-1r and anti-erbb3 antibodies Jul. 02, 2013
  • Patent Title: Bispecific binding agents for modulating biological activity May. 14, 2013
  • Patent Title: Liposomes useful for drug delivery Dec. 11, 2012
  • Patent Title: Bispecific binding agents for modulating biological activity Feb. 28, 2012
  • Patent Title: Antibodies against erbb3 and uses thereof Dec. 07, 2010
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of MACK in WallStreetBets Daily Discussion

MACK News

Recent insights relating to MACK

CNBC Recommendations

Recent picks made for MACK stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MACK

Corporate Flights

Flights by private jets registered to MACK